Data justify further research on potential of psychedelics in treating psychiatric disorders
The Brown University Psychopharmacology Update May 6, 2020 DOI: 10.1002/pu.30581 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Literature review Peer reviewed |
|---|---|
| Topics | MDMA Psilocybin |
| Keywords | Hallucinogen Drug Pharmacology |
| Citations | 1 |
| Key findings | Research findings to date do not support the use of psychedelic compounds in treating psychiatric disorders, but the existing body of research justifies continued investigation. |
Abstract
Although research findings to date do not support the use of psychedelic compounds in the treatment of psychiatric disorders, the existing body of research justifies continued investigation, a literature review concludes. The review found the most significant evidence supporting use of psilocybin and 3,4‐methylenedioxymethamphetamine (MDMA). Both of these drugs have been given “breakthrough therapy” designation by the Food and Drug Administration (FDA), which is intended to expedite the evaluation and development of drug candidates that might offer significant advantages over existing treatments for serious illnesses.
Comparable studies
Other narrative reviews on MDMA, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Human Pharmacology of MDMA | 2004 | Review | |
| Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research | 2001 | Review | |
| 3,4‐Methylenedioxymethamphetamine (MDMA, “Ecstasy”): pharmacology and toxicology in animals and humans | 1994 | Review | |
| (±)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-Induced Serotonin Neurotoxicity: Studies in Animals | 2000 | Review | |
| Amphetamine toxicities | 2010 | Review |